ABBV's Call-Heavy Options Setup Suggests $240 Breakout Potential Amid Bullish Fundamentals

• ABBV surges 2.34% to $229.62, trading near 30D support/resistance cluster at $227.52–$228.01
• Call open interest dominates at $240 strike (3,505 contracts), with block trade of 6,138 shares in the $230 call
• Bollinger Bands show price near upper band ($240.10), while RSI hovers at neutral 48.97
• Clinical trial wins at ASH 2025 and 56% earnings growth projections fuel long-term optimism

The stock is clearly in a bullish sweet spot right now. Options data and technicals align on a potential $240 breakout, while fundamentals suggest AbbVie’s momentum isn’t slowing down.The Call-Put Imbalance and Whale Moves Painting a Bullish Picture

Options traders are betting big on ABBV’s upside. The $240 call (ABBV20251205C240) leads this Friday’s open interest with 3,505 contracts—nearly double the next strike. That’s not just noise; it’s a price level where smart money sees a high-probability target. The $230 call (ABBV20251205C230) also shows heavy interest, with a massive block trade of 6,138 shares executed recently. Think of it like a football team stacking defenders at the goal line—they’re bracing for a big play.

On the downside, puts dominate at $222.50 (697 OI) and the extreme $160 strike (632 OI). That lower-body panic isn’t matching the call-side confidence. The put/call ratio of 0.77 (calls > puts) reinforces the bullish tilt. But don’t ignore the $160 puts—they hint at potential volatility if the stock stumbles, maybe from earnings misses or broader market jitters.

Bullish Pipeline News Fuels Long-Term Optimism

AbbVie’s recent clinical trial wins at ASH 2025 are more than just headlines. A 79% risk reduction in follicular lymphoma and 81% response rates in multiple myeloma aren’t numbers to dismiss. These results validate AbbVie’s R&D muscle and hint at future revenue streams. Combine that with 56% earnings growth projections and a Zacks Rank #3, and you’ve got a stock that’s both fundamentally sound and technically primed.

The market’s reaction? Options traders are pricing in optimism. The $240 call-heavy setup suggests they expect these fundamentals to translate into a price breakout. But here’s the catch: if the ASH data underwhelms retail investors or the broader market corrects, those $160 puts could suddenly look prescient.

Trade Ideas: Calls on $240, Puts for Protection

For the aggressive: Buy the ABBV20251205C240 call. If ABBV holds above its 30D support at $227.52, this strike becomes a high-conviction play. Target $245–$250 by expiration (Dec 5), where Bollinger Bands and 200D MA confluence create natural resistance.

For the cautious: Pair that call with the ABBV20251205P222.5 put. It’s the cheapest downside hedge at 697 OI, protecting against a pullback to the $214 lower Bollinger band. Or go longer-dated with the ABBV20251212C235 call (241 OI) for a safer, multi-week trade.

Stock buyers: Consider entry near $227.52 if support holds. First target is the $230–$235 resistance cluster, with a stretch goal of $240.10 (Bollinger upper band). Use the $224.52 intraday low as a hard stop.

Volatility on the Horizon

This isn’t a "buy and forget" trade. With earnings estimates rising and ASH 2025 data still fresh, ABBV could see wild swings. The options market is already pricing in that volatility—calls are expensive, but so is the potential reward. Keep an eye on next Friday’s options (Dec 12) as a barometer for longer-term sentiment. If the $235/240 calls gain traction, it’ll signal the bulls are taking control for good.

Bottom line: ABBV is at a crossroads. The technicals and options data scream "breakout," while fundamentals back it up. But don’t ignore the $160 put whisperers—they’re there for a reason. Play it smart: take profits at $240, lock in hedges, and stay nimble. This stock isn’t done moving yet.